New Analysis of Pombiliti(R) (cipaglucosidase alfa-atga) + Opfolda(R) (miglustat) Published in Muscle and Nerve
(NasdaqGM:FOLD), PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve. In this new publication, based on a […]